While Patients randomized to paroxetine were significantly less likely to relapse than comparably treated patients who were randomized to placebo.Subgroup analyses did not indicate that there were any differences in treatment outcomes as a function of age or gender.Studies 1 and 2 were flexible-dose studies comparing paroxetine (20 to 50 mg daily) and placebo. Conversely, at least 14 days should be allowed after stopping paroxetine Do not start paroxetine tablets in a patient who is being treated with linezolid or methylene blue because there is increased risk of serotonin syndrome or NMS-like reactions. This medicine should come with a Medication Guide. 2,000 mg of paroxetine (33 times the maximum recommended daily dose) in a patient who recovered.

Such symptoms should be reported to the patient's prescriber or health professional, especially if they are severe, abrupt in onset, or were not part of the patient's presenting symptoms.

While the clinical trials did not reveal any tendency for any drug-seeking behavior, these observations were not systematic and it is not possible to predict on the basis of this limited experience the extent to which a CNS-active drug will be misused, diverted, and/or abused once marketed.
Since both drugs exhibit nonlinear pharmacokinetics, the above studies may not address the case where the 2 drugs are both being chronically dosed. In pooled clinical trials of immediate-release paroxetine

I started a 10mg dose (from 20mg) for 4weeks and besides some of the physical side effects and mild emotional effects (which lasted for about a week), it wasn't too terrible. Dosage should not exceed 40 mg/day.At least 14 days should elapse between discontinuation of an MAOI intended to treat depression and initiation of therapy with paroxetine. affected by the induction or inhibition of drug-metabolizing enzymes.When a single oral 30-mg dose of paroxetine was administered at phenytoin steady state (300 mg once daily for 14 days), paroxetine AUC and T½ were reduced (by an average of 50% and 35%, respectively) compared to paroxetine administered alone. If intolerable symptoms occur following a decrease in the dose or upon discontinuation of treatment, then resuming the previously prescribed dose may be considered. The findings from these studies are summarized below: Other studies have found varying results as to whether there was an increased risk of overall, cardiovascular, or specific congenital malformations. Results: The mean pre-treatment ejaculatory latency time (ELT) of both group A and B was 0.4 min (range 0-1 min) in 205 intercourses at a frequency of 0.4 intercourses per week.

Serotonin syndrome symptoms may include mental status changes (e.g., agitation, hallucinations, coma), autonomic instability (e.g., tachycardia, labile blood pressure, hyperthermia), neuromuscular aberrations (e.g., hyperreflexia, incoordination) and/or gastrointestinal symptoms (e.g., nausea, vomiting, diarrhea). are pregnant, may be pregnant, or plan to become pregnant. Conversely, adverse effects could result from displacement since there is a potential for interactions.Although paroxetine has not been shown to increase the impairment of mental and motor skills caused by alcohol, patients should be advised to avoid alcohol while taking paroxetine.Patients should be advised to notify their physician if they become pregnant or intend to become pregnant during therapy.

In the majority of patients, these events were mild to moderate and were self-limiting and did not require medical intervention.

Before starting paroxetine, tell your healthcare provider if you: Your healthcare provider or pharmacist can tell you if it is safe to take paroxetine with your other medicines. Patients receiving warfarin therapy should be carefully monitored when paroxetine is initiated or discontinued. Monitor cardiac rhythm and vital signs. Signs and symptoms associated with more severe and/or acute cases have included hallucination, syncope, seizure, coma, respiratory arrest, and death. while taking paroxetine.

Side Effects. Like many other drugs, paroxetine is secreted in human milk, Paroxetine does not alter the The mean elimination half-life is approximately 21 hours (CV 32%) after oral dosing of 30 mg tablets daily for 30 days of Paroxetine hydrochloride. there have been reports of serious, sometimes fatal, reactions including hyperthermia, rigidity, myoclonus, autonomic instability with possible rapid fluctuations of vital signs, and mental status changes that include extreme agitation progressing to delirium and coma. SSRIs and SNRIs, including paroxetine, may increase the risk of bleeding events. In a fixed-dose study comparing placebo and 10, 20, and 40 mg of paroxetine in the treatment of panic disorder, there was no clear relationship between adverse events and the dose of paroxetine to which patients were assigned, except for asthenia, dry mouth, anxiety, libido decreased, tremor, and abnormal ejaculation. Treatment-Emergent Adverse Experience Incidence in Placebo-Controlled Clinical Trials for Obsessive Compulsive Disorder, Panic Disorder, and Social Anxiety DisorderTable 4.

The recommended and initial dosage is 20 mg/day. Due to the large volume of distribution of this drug, forced diuresis, dialysis, hemoperfusion, or exchange transfusion are unlikely to be of benefit.A specific caution involves patients who are taking or have recently taken paroxetine who might ingest excessive quantities of a tricyclic antidepressant. frequencies cannot be compared with figures obtained from other clinical investigations Patients with these diagnoses were excluded from clinical studies during the product’s premarket testing.
While these events are generally self-limiting, there have been reports of serious discontinuation symptoms. In many cases, this hyponatremia appears to be the result of the syndrome of inappropriate antidiuretic hormone secretion (SIADH). All rights reserved. rate than that seen in placebo-treated patients.